Research Site

Waukesha, Wisconsin 53226

2 studies enrolling now · 13 studies all time

What they study most

Acid Reflux Disease, Breast Cancer, Carcinoma, Cost Sharing, Acute Coronary Syndrome, Diabetes Mellitus, Type 2, ER-Positive HER2-Negative Breast Cancer, Endometrial Cancer, Fallopian Tube Cancer, GERD, Heart Failure, Heartburn, Malignant Solid Tumour

Studies at this site

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. — Recruiting now
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) — Recruiting now
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer — Running, not enrolling
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) — Running, not enrolling
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue — Completed
Dimethyl Fumarate (DMF) Observational Study — Completed
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer — Stopped early
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
Iressa Expanded Access Program (EAP) — Completed
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms — Completed